{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T01:54:11Z","timestamp":1768874051343,"version":"3.49.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.coph.2022.102307","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T06:30:51Z","timestamp":1667457051000},"page":"102307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Current treatment and molecular targets for axial spondyloarthritis: Evidence from randomized controlled trials"],"prefix":"10.1016","volume":"67","author":[{"given":"Rouhin","family":"Sen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2799-3036","authenticated-orcid":false,"given":"Liron","family":"Caplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2022.102307_bib1","article-title":"EVALUATION OF DIAGNOSTIC CRITERIA FOR ANKYLOSING SPONDYLITIS. A proposal for modification of the New York criteria","volume":"27","author":"Van Der Linden Hans Valkenburg","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102307_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/BOR.0000000000000475","article-title":"Epidemiology of axial spondyloarthritis: an update","volume":"30","author":"Wang","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.coph.2022.102307_bib3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13075-018-1644-6","article-title":"The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis","volume":"20","author":"Zhao","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coph.2022.102307_bib4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40744-018-0124-4","article-title":"Healthcare utilization and direct costs in patients with ankylosing spondylitis using a large US administrative claims database","volume":"5","author":"Walsh","year":"2018","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.coph.2022.102307_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/2040622317743486","article-title":"New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice","volume":"9","author":"Dubash","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.coph.2022.102307_bib6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nrrheum.2016.42","article-title":"New evidence on the management of spondyloarthritis","volume":"12","author":"Sieper","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coph.2022.102307_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4081\/reumatismo.2015.853","article-title":"The role of biomechanical factors in ankylosing spondylitis: the patient's perspective","volume":"67","author":"Ansell","year":"2016","journal-title":"Reumatismo"},{"key":"10.1016\/j.coph.2022.102307_sref8","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 update of the American college of rheumatology\/spondylitis association of America\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102307_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key152","article-title":"Therapies in ankylosing spondylitis\u2014from clinical trials to clinical practice","volume":"57","author":"Tahir","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.coph.2022.102307_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001005","article-title":"Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study","volume":"5","author":"Baraliakos","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.coph.2022.102307_bib11","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1517\/13543784.2014.899351","article-title":"Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis","volume":"23","author":"Braun","year":"2014","journal-title":"Expet Opin Invest Drugs"},{"key":"10.1016\/j.coph.2022.102307_bib12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41584-020-0454-9","article-title":"Revisiting the gut\u2013joint axis: links between gut inflammation and spondyloarthritis","volume":"16","author":"Gracey","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coph.2022.102307_bib13","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/art.37937","article-title":"In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis","volume":"65","author":"Appel","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102307_bib14","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102307_bib15","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102307_bib16","article-title":"A\u00a0spontaneous model of spondyloarthropathies that develops bone loss and pathological bone formation: a process regulated by IL27RA-\/- and mutant-p53","volume":"13","author":"Dibra","year":"2018"},{"key":"10.1016\/j.coph.2022.102307_bib17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nri2295","article-title":"TH17 cells in development: an updated view of their molecular identity and genetic programming","volume":"8","author":"Dong","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coph.2022.102307_bib18","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41584-019-0294-7","article-title":"The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis","volume":"15","author":"Sieper","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coph.2022.102307_bib19","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.immuni.2004.08.018","article-title":"Interleukin-17 family members and inflammation","volume":"21","author":"Kolls","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.coph.2022.102307_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.71.1.1","article-title":"IL-17: prototype member of an emerging cytokine family","volume":"71","author":"Aggarwal","year":"2002","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.coph.2022.102307_bib21","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1084\/jem.20071978","article-title":"Regulation of inflammatory responses by IL-17F","volume":"205","author":"Yang","year":"2008","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.coph.2022.102307_bib22","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.coph.2022.102307_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.immuni.2006.01.001","article-title":"TGF\u03b2 in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells","volume":"24","author":"Veldhoen","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.coph.2022.102307_bib24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature04754","article-title":"Transforming growth factor-\u03b2 induces development of the TH17 lineage","volume":"441","author":"Mangan","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.coph.2022.102307_bib25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.coph.2022.102307_bib26","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/intimm\/dxh111","article-title":"Involvement of IL-17 in Fas ligand-induced inflammation","volume":"16","author":"Umemura","year":"2004","journal-title":"Int Immunol"},{"key":"10.1016\/j.coph.2022.102307_bib27","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.4049\/jimmunol.177.10.6852","article-title":"CD8+ IL-17-producing T cells are important in effector functions for the elicitation of contact hypersensitivity responses","volume":"177","author":"He","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.coph.2022.102307_bib28","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nri2800","article-title":"Innate IL-17-producing cells: the sentinels of the immune system","volume":"10","author":"Cua","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coph.2022.102307_bib29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.immuni.2009.06.020","article-title":"Interleukin-17-Producing \u03b3\u03b4 T cells selectively expand in response to pathogen products and environmental signals","volume":"31","author":"Martin","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.coph.2022.102307_bib30","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/art.39464","article-title":"Sexual dimorphism in the Th17 signature of ankylosing spondylitis","volume":"68","author":"Gracey","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102307_bib31","article-title":"Bimekizumab blocks T cell-mediated osteogenic differentiation of periosteal stem cells: coupling pathological bone formation to IL-17a and IL-17F signaling","volume":"69","author":"Shah","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102307_bib32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","article-title":"Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"79","author":"van der Heijde","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.coph.2022.102307_sref33","article-title":"POS0939 bimekizumab in patients with active NON- radiographic axial spondyloarthritis: 24-WEEK efficacy & safety from be mobile 1, a phase 3, multicentre, randomised, placebo-controlled study","volume":"81","author":"Deodhar","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.coph.2022.102307_bib34","article-title":"OP0019 bimekizumab in patients with active ankylosing spondylitis: 24-WEEK efficacy & safety from be mobile 2, a phase 3, multicentre, randomised, placebo-controlled study","volume":"81","author":"Van der Heijde","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102307_bib35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4049\/jimmunol.177.1.36","article-title":"Cutting edge: interleukin 17 signals through a heteromeric receptor complex","volume":"177","author":"Toy","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.coph.2022.102307_bib36","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coph.2022.102307_bib37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cyto.2013.03.014","article-title":"The activation and regulation of IL-17 receptor mediated signaling","volume":"62","author":"Song","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.coph.2022.102307_sref38","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/annrheumdis-2020-219406","article-title":"Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial","volume":"80","author":"Wei","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102307_bib39","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/1756-185X.13094","article-title":"Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies","volume":"20","author":"Wei","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.coph.2022.102307_bib40","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/14397595.2018.1538004","article-title":"Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)","volume":"30","author":"Kishimoto","year":"2020","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.coph.2022.102307_bib41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102307_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keab740","article-title":"A\u00a0review of JAK\u2013STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition","volume":"61","author":"McInnes","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.coph.2022.102307_bib43","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102307_bib44","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102307_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102307_sref46","article-title":"Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial","author":"van der Heijde","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102307_bib47","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102307_bib49","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102307_bib50","author":"Carvalho"},{"key":"10.1016\/j.coph.2022.102307_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2021.685280","article-title":"From science to success? Targeting tyrosine kinase 2 in spondyloarthritis and related chronic inflammatory diseases","volume":"12","author":"Hromadov\u00e1","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.coph.2022.102307_sref52","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1172\/JCI126567","article-title":"TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis","volume":"130","author":"Gracey","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.coph.2022.102307_bib53","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s40674-018-0095-1","article-title":"Novel therapeutic targets in axial spondyloarthritis","volume":"4","author":"Worth","year":"2018","journal-title":"Curr Treat Options Rheumatol"},{"key":"10.1016\/j.coph.2022.102307_bib54","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13075-019-1879-x","article-title":"Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an i","volume":"21","author":"Taylor","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coph.2022.102307_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg1210","article-title":"Macrophage migration inhibitory factor drives pathology in a mouse model of spondyloarthritis and is associated with human disease","author":"Nakamura","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2022.102307_bib56","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/art.40175","article-title":"Macrophage migration inhibitory factor induces inflammation and predicts spinal progression in ankylosing spondylitis","volume":"69","author":"Ranganathan","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102307_bib57","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1111\/bcp.14289","article-title":"Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours","volume":"86","author":"Mahalingam","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.coph.2022.102307_bib58","article-title":"The HLA-B2705 peptidome","volume":"62","author":"Halevi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102307_bib59","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.27188","article-title":"The HLA-B27 peptidome: building on the cornerstone","volume":"62","author":"L\u00f3pez de Castro","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102307_bib60","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/art.40028","article-title":"Discovery of T Cell receptor \u03b2 motifs specific to HLA\u2013B27\u2013positive ankylosing spondylitis by deep repertoire sequence analysis","volume":"69","author":"Faham","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102307_bib61","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/rheumatology\/kex517","article-title":"CD8+ T cells with characteristic T cell receptor beta motif are detected in blood and expanded in synovial fluid of ankylosing spondylitis patients","volume":"57","author":"Komech","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.coph.2022.102307_sref62","doi-asserted-by":"crossref","DOI":"10.24075\/brsmu.2018.064","article-title":"Testing of monoclonal antibodies against the T-cell receptor associated with ankylosing spondylitis","author":"Israelson","year":"2018","journal-title":"Bull Russ State Med Univ"},{"key":"10.1016\/j.coph.2022.102307_bib63","article-title":"0489 CC-99677: a novel, oral, selective MK2 inhibitor with sustainable multi-cytokine inhibition for the treatment of ankylosing spondylitis and other inflammatory diseases","volume":"73","author":"Mensah","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102307_sref64","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13075-022-02850-6","article-title":"CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production","volume":"24","author":"Gaur","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coph.2022.102307_bib65","first-page":"1","article-title":"Discovery of CC-99677, a selective targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune disorders","volume":"2","author":"Malona","year":"2022","journal-title":"Transl Res"},{"key":"10.1016\/j.coph.2022.102307_bib66","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jbspin.2015.10.011","article-title":"Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthritis: prevalence and associated phenotype","volume":"83","author":"Maillet","year":"2016","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.coph.2022.102307_bib67","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/ard.62.5.455","article-title":"Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy","volume":"62","author":"Hoffman","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102307_bib68","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000080081","article-title":"Inflammatory bowel disease-specific autoantibodies in HLA-B27-associated spondyloarthropathies: increased prevalence of ASCA and pANCA","volume":"70","author":"T\u00f6r\u00f6k","year":"2004","journal-title":"Digestion"},{"key":"10.1016\/j.coph.2022.102307_bib69","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/rheumatology\/kem324","article-title":"Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment","volume":"47","author":"Aydin","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.coph.2022.102307_bib70","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/gene.2010.17","article-title":"Elucidating the chromosome 9 association with AS; CARD9 is a candidate gene","volume":"11","author":"Pointon","year":"2010","journal-title":"Gene Immun"},{"key":"10.1016\/j.coph.2022.102307_bib71","article-title":"STAT1 hyperphosphorylation and defective IL12R\/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis","volume":"6","author":"Smeekens","year":"2011"},{"key":"10.1016\/j.coph.2022.102307_bib72","doi-asserted-by":"crossref","DOI":"10.1126\/science.1200439","article-title":"Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity","volume":"332","author":"Puel","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.coph.2022.102307_bib73","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1056\/NEJMoa0810719","article-title":"A\u00a0homozygous CARD9 mutation in a family with susceptibility to fungal infections","volume":"361","author":"Glocker","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102307_bib74","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/gene.2010.17","article-title":"Elucidating the chromosome 9 association with AS; CARD9 is a candidate gene","volume":"11","author":"Pointon","year":"2010","journal-title":"Genes Immun"},{"key":"10.1016\/j.coph.2022.102307_bib75","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/ng.513","article-title":"Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci","volume":"42","author":"Reveille","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.coph.2022.102307_bib76","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/art.34423","article-title":"\u03b2-glucan triggers spondylarthritis and Crohn's disease-like ileitis in SKG mice","volume":"64","author":"Ruutu","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102307_bib77","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nri2939","article-title":"Immunity to fungal infections","volume":"11","author":"Romani","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coph.2022.102307_bib78","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/cei.13021","article-title":"Fungal-derived cues promote ocular autoimmunity through a Dectin-2\/Card9-mediated mechanism","volume":"190","author":"Brown","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coph.2022.102307_bib79","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/35013070","article-title":"Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin","volume":"405","author":"Borovikova","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.coph.2022.102307_bib80","article-title":"Vagus nerve stimulation attenuates systemic inflammation and improves survival in a rat heatstroke model","volume":"8","author":"Yamakawa","year":"2013"},{"key":"10.1016\/j.coph.2022.102307_bib81","doi-asserted-by":"crossref","first-page":"8284","DOI":"10.1073\/pnas.1605635113","article-title":"Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis","volume":"113","author":"Koopman","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coph.2022.102307_bib82","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2796.2010.02321.x","article-title":"The pulse of inflammation: heart rate variability, the cholinergic anti-inflammatory pathway and implications for therapy","volume":"269","author":"Huston","year":"2011","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.coph.2022.102307_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.resp.2016.03.014","article-title":"Vagal nerve stimulation attenuates IL-6 and TNF\u03b1 expression in respiratory regions of the developing rat brainstem","volume":"229","author":"Johnson","year":"2016","journal-title":"Respir Physiol Neurobiol"},{"key":"10.1016\/j.coph.2022.102307_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105328","article-title":"Relationship between vagal tone, cortisol, TNF-alpha, epinephrine and negative affects in crohn's disease and irritable bowel syndrome","volume":"9","author":"Pellissier","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2022.102307_bib85","doi-asserted-by":"crossref","DOI":"10.4137\/CGast.S31779","article-title":"Bioelectrical stimulation for the reduction of inflammation in inflammatory bowel disease","author":"Marshall","year":"2015","journal-title":"Clin Med Insights Gastroenterol"},{"key":"10.1016\/j.coph.2022.102307_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01452","article-title":"The vagus nerve in the neuro-immune Axis: implications in the pathology of the gastrointestinal tract","author":"Bonaz","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2022.102307_bib87","article-title":"Emotional overactivity in patients with irritable bowel syndrome","volume":"30","author":"Fournier","year":"2018","journal-title":"Neuro Gastroenterol Motil"},{"key":"10.1016\/j.coph.2022.102307_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpsyt.2020.00229","article-title":"Interoceptive abilities in inflammatory bowel diseases and irritable bowel syndrome","volume":"11","author":"Fournier","year":"2020","journal-title":"Front Psychiatr"},{"key":"10.1016\/j.coph.2022.102307_bib89","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/rheumatology\/keg405","article-title":"Acupuncture for chronic low back pain in older patients: a randomized, controlled trial","volume":"42","author":"Meng","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.coph.2022.102307_bib90","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00296-009-1206-y","article-title":"Complementary and alternative medicine use in rheumatoid arthritis: proposed mechanism of action and efficacy of commonly used modalities","volume":"30","author":"Efthimiou","year":"2010","journal-title":"Rheumatol Int"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222001345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222001345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:57:19Z","timestamp":1761461839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489222001345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":89,"alternative-id":["S1471489222001345"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2022.102307","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current treatment and molecular targets for axial spondyloarthritis: Evidence from randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2022.102307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102307"}}